FRS
0.026
160%
OCT
0.045
-42.3%
CRS
0.062
138.5%
NRZ
0.002
-33.3%
AVE
0.007
133.3%
CHM
0.006
-25%
LAT
0.074
111.4%
JAV
0.003
-25%
RLL
0.004
100%
HYD
0.019
-24%
SCN
0.027
80%
DUN
0.033
-23.3%
BP8
0.005
66.7%
TFL
0.01
-23.1%
EVR
0.005
66.7%
EXR
0.034
-22.7%
RGL
0.005
66.7%
GLL
0.007
-22.2%
SLM
0.105
66.7%
OZM
0.125
-21.9%
RR1
0.013
62.5%
TMG
0.036
-21.7%
RAS
0.025
56.3%
AGH
0.02
-20%
BGE
0.03
50%
CRR
0.004
-20%
CDT
0.003
50%
EM2
0.008
-20%
TMK
0.003
50%
CVL
1.06
-19.4%
BSX
0.051
45.7%
NWM
0.013
-18.8%
VIT
0.112
41.8%
AQD
0.04
-18.4%
CMO
0.024
41.2%
BUS
0.155
-18.4%
TOR
0.1
40.8%
LOT
0.195
-17%
EXT
0.018
38.5%
PUA
0.01
-16.7%
Optiscan Imaging (ASX:OIL) has unveiled its next generation microscopic medical imaging device known as InForm, specifically designed to transform pathology workflows by delivering real-time digital insights at point of contact with a tissue sample.
 
🔹Improves efficiency and accuracy of analysis and diagnosis across all pathology workflows.
🔹Expands Optiscan’s product portfolio into the pathology market, marking a pivotal milestone in advancing the company's strategic objectives.
🔹Enhances the entire pathology workflow across a range of settings, enabling efficiencies and on-the-spot digital decision making for pathologists to improve diagnostic capabilities.
 
“The reveal of our revolutionary InForm™ device, the latest addition to our ever-expanding suite of hardware products, represents a significant advancement in the evolution of digital pathology. InForm™ has the ability to enhance the entire pathology workflow from bedside to laboratory and beyond, by improving the speed, accuracy and flexibility of testing, analysis and diagnosis." - Optiscan CEO and Managing Director, Dr Camile Farah
Baby goods retailer Baby Bunting (ASX: BBN) has reported a boost in profitability in the first half of the 2025 financial year driven by an uptick in sales, a rise in new customer acquisitions, and gross margin expansion. The company is implementing a series of strategic initiatives to fuel further growth.

👶 Net profit after tax (NPAT) of $4.8 million on a pro-forma basis up by 37% from same time last year as new customer acquisitions rise by 12%
🍼 Gross margin expands by 260 basis points to 39.8 per cent with the company on track to meet its margin target for the full financial year
🧸 Progresses new store rollout and refurbishment of existing shops to fuel growth 

“Our focus on driving sales through range innovation and new customer acquisition is delivering results. Newness in our ranges continues to resonate, with new customer acquisition up 12% on the prior period. Our exclusive branded products remain a key traffic driver and, with a strong pipeline of exclusive launches in the second half, we expect this momentum to continue.” – Mark Teperson, Baby Bunting Chief Executive Officer
Australian retailer Adore Beauty (ASX: ABY) has reported a sharp rise in profitability and margin growth in the first half of FY25 as its refreshed operational strategy focused on disciplined cost management and the expansion of its retail network begins to take shape.

💄 Operating earnings (EBIT) of $2.8 million in H1 FY25 up by 126% from same time last year
🧴 Delivers cash flow positive half-year and record gross margin of 36.2%
💅 Launches physical store roll out with opening of first shop in Victoria as it targets national retail network of 25 shops 

“Our half-year results demonstrate the strength of the Adore Beauty brand and the early momentum of our strategy refresh focusing in the near-term on enhancing quality of earnings and optimising our operating model. I am delighted with the demonstrated gains in gross margin which delivered material improvement and the subsequent 126% growth in EBIT in the half.” – Sacha Laing, Adore Beauty Chief Executive Officer
Ahead of appearing at the Stocks On Track event, Kingston Resources (ASX:KSN) Managing Director Andrew Corbett speaks with The Stock Network's Lel Smits and highlights:

⛏️ Rising gold price and operations
⚒️ Maiden underground Ore Reserve at Mineral Hill
⛰️ Mineral Hill upside
Medical technology business Artrya (ASX: AYA) has pocketed $15 million from a placement as it looks to fast track the commercialisation of its patented Salix artificial intelligence (AI) platform used to detect heart disease.

⚕️ Proceeds will be used to accelerate regulatory approvals in the lucrative US market, as well as customer implementation, clinical studies, and regulatory costs
🧑‍⚕️ Clearance from the US Food and Drug Administration (FDA) expected soon
🏥 Adds to recent contract win with Australia’s second largest diagnostic imaging provider, Sonic Healthcare

“The Company continues the regulatory pathway to expand FDA approvals this year with a portion of Placement proceeds applied to accelerate regulatory applications for our SCP & SCF products, along with customer implementation costs including the Sonic Healthcare Australia Radiology commercial agreement announced on 12 February 2025.” – Mathew Regan, Artrya Chief Executive Officer
Health and fitness club provider Viva Leisure (ASX: VVA) has delivered a strong set of numbers for the first half of the 2025 financial year with membership growth and network expansion propelling revenue and profitability to record levels.

🏋️ Revenue up by 25% from the same time last year as memberships soar by 72%
💪 Operating earnings (EBITDA) up by 26% year-on-year with net profit after tax up by 15%
🏃‍♀️ Prioritising free cash flow generation, network optimisation, and expansion of technology-driven offerings to drive further growth

“1H FY25 has been a phenomenal period for Viva Leisure, with record-breaking results reflecting the strength of our diversified strategy and the resilience of our business model. Our expanding corporate and franchise network, combined with our high-margin technology and payments division, continues to drive sustainable and profitable growth.” – Harry Konstantinou, Viva Leisure Chief Executive Officer and Managing Director
If you like to buy at Chemist Warehouse you may be interested to know that from today, it today became part of a listed company. Sigma Healthcare is the listed company that merged with Chemist Warehouse, debuting today as a merged entity trading under the code SIG.
Diversified digital health platform business Vitura Health (ASX: VIT) has sealed $5.1 million from a strategic placement to fund its new acquisition of leading Australian medicinal cannabis clinic business, Candor Medical.

🧑‍⚕️ Propels Vitura into one of Australia’s largest medicinal cannabis clinic providers by growing its consolidated consultation numbers to more than 100,000 each year 
💊 Expands Vitura’s specialty healthcare division with the deal expected to deliver a material boost to revenue and operating earnings (EBITDA)
🥼 Backed by $5.1 million placement to an entity associated with renowned high-net-worth businessman, Professor Khalil Shahin

“We are very excited by the opportunities unlocked by this acquisition which we see as a great opportunity to bring together two leaders in the field, both of whom have a deep alignment on the commitment to providing patients with personalised care and which reinforces our goal to make specialty healthcare product and service verticals more accessible to millions of patients across Australia.” – Geoff Cockerill, Vitura Health Chief Executive Officer

Magnetic Resources (ASX:MAU): Developing high grade gold in WA’s goldfields

Kingston Resources (ASX:KSN): Growing gold production in the historic Cobar basin of New South Wales

Articles

FinTok

IPOs

ASX 200

Today's Date: 2025-02-19
Market Status: Closed
Last Update: 19-02-2025

Top Gainers

FRS0.026 160%
CRS0.062 138.5%
AVE0.007 133.3%
LAT0.074 111.4%

Biggest Losers

OCT0.045 -42.3%
NRZ0.002 -33.3%
CHM0.006 -25%
JAV0.003 -25%

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy